Beverly Wilshire Ltd. FY2025 Financial Results Review: Key Risks Highlighted by Auditor’s Disclaimer

Beverly Wilshire Ltd., a Singapore-listed healthcare group, released its audited financial statements for the year ended 31 December 2025. The report includes a notable disclaimer of opinion by its independent auditor, flagging significant uncertainties regarding the Group’s ability to continue as a going concern. Below, we analyze the key financial metrics, audit issues, and management responses, and provide an outlook assessment for investors.

Key Financial Metrics

Note: No explicit quarterly breakdowns or EPS data were provided in the report.

Audit Disclaimer and Key Concerns

• Disclaimer of Opinion: The auditor, UHY Lee Seng Chan & Co, did not express an opinion on the FY2025 financial statements due to:
  • Inability to verify opening balances (as FY2024 also carried a disclaimer)
  • Material uncertainties about going concern
  • Insufficient support for management’s cash flow forecasts and key operational assumptions
  • Impairment review of non-current assets lacking external evidence and proper methodology
• Going Concern Doubts: The Group recorded negative operating cash flow and a net loss. A substantial portion of current assets is tied up as deposit for an acquisition, not available for working capital. Significant liabilities are due within 12 months.
• Reliance on Future Funding: Management’s ability to continue as a going concern is contingent on:
  • Raising additional capital (S\$275,000 already raised post-year-end, with plans for >S\$2 million more)
  • Debt capitalisation (S\$163,000 of debts converted to equity post-year-end)
  • A major bank loan (RM28 million/S\$9 million) that remains subject to approval
  • Financial support from the controlling shareholder

  However, auditors could not verify the realism of these assumptions.

• Impairment Assessment: The Group did not provide sufficient external support for the assumptions used in impairment tests for property, plant, equipment, intangibles, and investments in subsidiaries. The required methodology to compare “fair value less costs of disposal” with “value in use” was not followed.

Recent and Planned Corporate Actions

• Fundraising: S\$275,000 raised post-year-end. Board intends to raise >S\$2 million more via equity and debt.
• Debt Capitalisation: S\$163,000 of outstanding remuneration and professional fees converted to equity.
• Planned Acquisition: Deposit of S\$2,612,000 paid (in shares) for a property acquisition (second floor of Tower A, Nobel Healthcare Park). The remaining S\$10.07 million (RM33.131 million) to be paid via cash (bank loan) and convertible bonds.
• Acquisition Pipeline: Company intends further acquisitions to support revenue and cash flow.

Management and Board Statements

The Board of Directors maintains the view that the financial statements should be prepared on a going concern basis, citing additional capital raised, debt capitalisation, shareholder support, and fundraising plans. However, the auditor’s report underscores that these measures are inherently uncertain and lacked sufficient audit evidence.

Material Risks and Outlook

• Liquidity Risks: The Group faces tight liquidity, with much of its current assets locked in acquisition deposits and significant short-term liabilities due.
• Uncertain Funding: The ability to secure planned funding (especially the large bank loan) is not assured.
• Operational Reliance: The company’s business plan depends on improvement in its Malaysian aesthetic medical operations and successful completion of acquisitions.
• Audit Concerns: Two consecutive years of disclaimer of opinion raises red flags on reliability of reported numbers and the company’s financial health.

Conclusion and Investor Recommendations

Overall Financial Performance and Outlook: The financial performance of Beverly Wilshire Ltd. appears weak, with negative operating cash flow, continued net losses (albeit narrowed), and a balance sheet burdened with short-term liabilities. The outlook is highly uncertain, contingent on fundraising, debt approvals, and operational turnaround—none of which are sufficiently reliable at this time according to the independent auditor.

Recommendations

• If you are currently holding this stock:
  
  Consider reviewing your position urgently. The auditor’s disclaimer and the company’s reliance on unproven funding sources and operational assumptions represent a high risk of further value erosion or even a going concern crisis. Risk-tolerant investors may choose to hold pending evidence of successful fundraising or operational turnaround, but should closely monitor company announcements and financial updates.
• If you are not currently holding this stock:
  
  It is advisable to remain on the sidelines until the company demonstrates tangible improvements in financial stability, secures reliable funding, and receives a clean audit opinion. The current risk profile is elevated, and alternative investments may offer a more stable risk-return profile.

Disclaimer: This analysis is strictly based on information disclosed in Beverly Wilshire Ltd.’s FY2025 financial report and does not constitute investment advice. Investors should conduct their own due diligence and consider their risk appetite before making any investment decisions.

View B Wilshire Ltd Historical chart here